Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

被引：0
|
作者：
P. G. Corrie
W. Qian
B. Basu
J. W. Valle
S. Falk
C. lwuji
H. Wasan
D. Palmer
M. Scott-Brown
J. Wadsley
S. Arif
J. Bridgewater
D. Propper
R. Gillmore
A. Gopinathan
R. Skells
P. Bundi
R. Brais
K. Dalchau
L. Bax
A. Chhabra
A. Machin
A. Dayim
K. McAdam
S. Cummins
L. Wall
R. Ellis
A. Anthoney
J. Evans
Y. T. Ma
C. Isherwood
A. Neesse
D. Tuveson
D. I. Jodrell
机构：
[1] Cambridge University Hospitals NHS Foundation Trust (Addenbrooke’s Hospital),Gastroenterology and Gastrointestinal Cancer Clinic
[2] Cancer Research UK—Cambridge Institute,undefined
[3] University of Cambridge,undefined
[4] University of Manchester and The Christie NHS Foundation Trust,undefined
[5] Bristol Haematology and Oncology Centre,undefined
[6] Leicester Royal Infirmary,undefined
[7] Hammersmith Hospital,undefined
[8] Imperial College,undefined
[9] Clatterbridge Cancer Centre,undefined
[10] University Hospital Coventry and Warwickshire,undefined
[11] Weston Park Hospital,undefined
[12] Velindre Cancer Centre,undefined
[13] UCL Cancer Institute,undefined
[14] Barts Cancer Institute,undefined
[15] The Royal Free Hospital,undefined
[16] Peterborough City Hospital,undefined
[17] Royal Surrey County Hospital,undefined
[18] Western General Hospital,undefined
[19] Royal Cornwall Hospitals,undefined
[20] St. James’s University Hospitals,undefined
[21] Beatson West of Scotland Cancer Centre,undefined
[22] University of Glasgow,undefined
[23] Queen Elizabeth Hospital,undefined
[24] University of Göttingen,undefined
[25] Cold Spring Harbor Laboratory,undefined
来源：
British Journal of Cancer | 2020年 / 122卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1760 / 1768
页数：8
相关论文
共 50 条
  • [21] Comparative effectiveness of FOLFIRINOX (FOL) versus gemcitabine and nab-paclitaxel (GNP) for the first-line treatment of metastatic pancreatic cancer
    Cheng, Wei-Han
    Sadeghi, Sarmad
    Lenz, Heinz-Josef
    Hay, Joel W.
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [22] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [23] Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma
    Trestini, Ilaria
    Carbognin, Luisa
    Peretti, Umberto
    Sperduti, Isabella
    Caldart, Alberto
    Tregnago, Daniela
    Avancini, Alice
    Auriemma, Alessandra
    Orsi, Giulia
    Pilotto, Sara
    Frulloni, Luca
    Capurso, Gabriele
    Bria, Emilio
    Reni, Michele
    Tortora, Giampaolo
    Milella, Michele
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] First line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma.
    Gulhati, Pat
    Prakash, Laura
    Katz, Matthew H. G.
    Wang, Xuemei
    Javle, Milind M.
    Shroff, Rachna T.
    Fogelman, David R.
    Lee, Jeffrey Edwin
    Tzeng, Ching-Wei David
    Lee, Jeffrey H.
    Weston, Brian
    Tamm, Eric P.
    Bhosale, Priya
    Koay, Eugene Jon
    Maitra, Anirban
    Wang, Huamin
    Wolff, Robert A.
    Varadhachary, Gauri R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [25] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [26] Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma
    McNulty, M.
    Dean, A.
    Das, A.
    Gordon, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel
    McSweeney, T.
    Das, A.
    O'Mahony, A.
    O'Tighearnaigh, F.
    O'Byrne, L.
    Feely, M.
    Passmore, E.
    Keane, S.
    Lanigan, S.
    Fitzgerald, S.
    Browne, T.
    De Beer, V.
    Dean, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S133 - S133
  • [28] Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial
    Assenat, E.
    de la Fouchardiere, C.
    Portales, F.
    Ychou, M.
    Debourdeau, A.
    Desseigne, F.
    Iltache, S.
    Fiess, C.
    Mollevi, C.
    Mazard, T.
    ESMO OPEN, 2021, 6 (06)
  • [29] Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from US perspective
    Shao, Hanqiao
    Fang, Hongshu
    Li, Yuan
    Jiang, Yunlin
    Zhao, Mingye
    Tang, Wenxi
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2024, 22 (01):
  • [30] Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
    Borazanci, Erkut
    Von Hoff, Daniel D.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (07) : 739 - 747
12345